Insulin Resistance Mediates the Association Between Vitamin D and Non‑Alcoholic Fatty Liver Disease

Caiyan Zou, Xuekui Liu, Maosheng He, Yan Sun, Yiquan Sang, Gangshan Peng, Yamei Ma, Houfa Geng, Jun Liang

Abstract


Background: Vitamin D (VD) deficiency and insulin resistance (IR) increase the risk of non‑alcoholic fatty liver disease (NAFLD), but few studies have explored the potential mechanisms by which IR mediates the association between VD and the pathogenesis of NAFLD at the genetic level using publicly available databases. Methods: This is a cross‑sectional study, and we utilized the National Health and Nutrition Examination Survey (NHANES) dataset, as well as data from GSE200765 obtained from the Gene Expression Omnibus (GEO) website. A total of 723 individuals who had completed liver ultrasound examination and the detection of VD levels were included in the final analysis. A gene expression dataset, GSE200765, was also downloaded from the GEO website, to explore the potential mechanism of VD and NAFLD. Results: In the NHANES data, covariates significantly differed in four VD categories, and the controlled attenuation parameter (CAP), vibration‑controlled transient elastography‑liver stiffness measurement (VCTE‑LSM), and IR were reduced with an increase in VD levels. Mediation analysis revealed that IR mediated the association between VD and both CAP and LSM, and the estimated mediation effects were 29.0% and 39.8%, respectively. Bioinformatics analysis showed that seven differentially expressed genes (DEGs) (solute carrier family 2 member 2 [SLC2A2], protein phosphatase 1 regulatory subunit 3E [PPP1R3E], CAMP responsive element binding protein 3‑like 3 [CREB3L3], Interleukin‑6 [IL‑6], peroxisome proliferator‑activated receptor gamma coactivator 1‑alpha [PPARGC1A], nuclear factor kappa B inhibitor alpha [NFKBIA], and phosphoenolpyruvate carboxykinase 2 [PCK2]) were enriched in the IR pathway in comparison groups (VD group vs. lipid group), suggesting that VD improved NAFLD via changed IR. Conclusions: VD deficiency and IR were the risk factors for NAFLD, and increased VD levels improved the status of NAFLD. The underlying mechanism may be that elevated VD levels reduced IR, which improved the expression of DEGs involved in the IR pathway.

Keywords


Insulin resistance; mediation analysis; national health and nutrition examination survey; non‑alcoholic fatty liver disease; vitamin D

Full Text:

PDF

References


Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease Meta analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016;64:73 84.

Isaacs S. Nonalcoholic fatty liver disease. Endocrinol Metab Clin North Am 2023;52:149 64.

Stefan N, Schick F, Birkenfeld AL, Häring H U, White MF. The role of hepatokines in NAFLD. Cell Metab 2023;35:236 52.

He Y, Su Y, Duan C, Wang S, He W, Zhang Y, et al. Emerging role of aging in the progression of NAFLD to HCC. Ageing Res Rev 2023;84:101833. doi: 10.1016/j.arr. 2022.101833.

Younossi ZM, Blissett D, Blissett R, Henry L, Stepanova M, Younossi Y, et al. The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe. Hepatology 2016;64:1577 86.

O’Hara J, Finnegan A, Dhillon H, Ruiz Casas L, Pedra G, Franks B, et al. Cost of non alcoholic steatohepatitis in Europe and the USA: The GAIN study. JHEP Rep 2020;2:100142. doi: 10.1016/j.jhepr. 2020.100142.

Barchetta I, Cimini FA, Cavallo MG. Vitamin D and metabolic dysfunction associated fatty liver disease (MAFLD): An update. Nutrients 2020;12:3302. doi: 10.3390/nu12113302.

Jarvis H, Craig D, Barker R, Spiers G, Stow D, Anstee QM, et al. Metabolic risk factors and incident advanced liver disease in non alcoholic fatty liver disease (NAFLD): A systematic review and meta analysis of population based observational studies. PLoS Med 2020;17:e1003100. doi: 10.1371/journal. pmed. 1003100.

Day CP, James OF. Steatohepatitis: A tale of two “hits”? Gastroenterology 1998;114:842 5.

Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 2010;363:1341 50.

Luo Y, Lin H. Inflammation initiates a vicious cycle between obesity and nonalcoholic fatty liver disease. Immun Inflamm Dis 2021;9:59 73.

Angelico F, Burattin M, Alessandri C, Del Ben M, Lirussi F. Drugs improving insulin resistance for non alcoholic fatty liver disease and/or non alcoholic steatohepatitis. Cochrane Database Syst Rev 2007:Cd005166. doi: 10.1002/14651858.CD005166. pub2.

Cigrovski Berkovic M, Rezic T, Bilic Curcic I, Mrzljak A. Semaglutide might be a key for breaking the vicious cycle of metabolically associated fatty liver disease spectrum? World J Clin Cases 2022;10:6759 68.

Kobayashi T, Okano T, Shida S, Okada K, Suginohara T, Nakao H, et al. Variation of 25 hydroxyvitamin D3 and 25 hydroxyvitamin D2 levels in human plasma obtained from 758 Japanese healthy subjects. J Nutr Sci Vitaminol (Tokyo) 1983;29:271 81.

Szymczak Pajor I, Śliwińska A. Analysis of association between vitamin D deficiency and insulin resistance. Nutrients 2019;11:794. doi: 10.3390/nu11040794.

Ravaioli F, Pivetti A, Di Marco L, Chrysanthi C, Frassanito G, Pambianco M, et al. Role of vitamin D in liver disease and complications of advanced chronic liver disease. Int J Mol Sci 2022;23:9016. doi: 10.3390/ijms23169016.

Barchetta I, Cimini FA, Cavallo MG. Vitamin D and metabolic dysfunction associated fatty liver disease (MAFLD): An update. Nutrients 2020;12:3302. doi: 10.3390/nu12113302.

Karatayli E, Stokes CS, Lammert F. Vitamin D in preclinical models of fatty liver disease. Anticancer Res 2020;40:527 34.

Berridge MJ. Vitamin D deficiency and diabetes. Biochem J 2017;474:1321 32.

Ding N, Yu RT, Subramaniam N, Sherman MH, Wilson C, Rao R, et al. A vitamin D receptor/SMAD genomic circuit gates hepatic fibrotic response. Cell 2013;153:601 13.

Han F F, Lv Y L, Gong L L, Liu H, Wan Z R, Liu L H. VDR Gene variation and insulin resistance related diseases. Lipids Health Dis 2017;16:157.

Ha Y, Hwang SG, Rim KS. The association between vitamin D insufficiency and nonalcoholic fatty liver disease: A population based study. Nutrients 2017;9:806. doi: 10.3390/ nu9080806.

Wang N, Chen C, Zhao L, Chen Y, Han B, Xia F, et al. Vitamin D and nonalcoholic fatty liver disease: Bi directional mendelian randomization analysis. EBioMedicine 2018;28:187 93.

Eliades M, Spyrou E, Agrawal N, Lazo M, Brancati FL, Potter JJ, et al. Meta analysis: Vitamin D and non alcoholic fatty liver disease. Aliment Pharmacol Ther 2013;38:246 54.

Wang X, Li W, Zhang Y, Yang Y, Qin G. Association between vitamin D and non alcoholic fatty liver disease/non alcoholic steatohepatitis: Results from a meta analysis. Int J Clin Exp Med 2015;8:17221 34.

Kim HS, Rotundo L, Kothari N, Kim SH, Pyrsopoulos N. Vitamin D is associated with severity and mortality of non alcoholic fatty liver disease: A US population based study. J Clin Transl Hepatol 2017;5:185 92.

Dal K, Uzman M, Ata N, Ertugrul DT, Bursa N, Caglayan M, et al. The effect of vitamin D status on non alcoholic fatty liver disease: A population based observational study. Endokrynol Pol 2023;74:63 6.

Zhang XL, Chen L, Yang J, Zhao SS, Jin S, Ao N, et al. Vitamin D alleviates non alcoholic fatty liver disease via restoring gut microbiota and metabolism. Front Microbiol 2023;14:1117644. doi: 10.3389/fmicb. 2023.1117644.

Zhu S, Wang Y, Luo F, Liu J, Xiu L, Qin J, et al. The level of vitamin D in children and adolescents with nonalcoholic fatty liver disease: A meta analysis. Biomed Res Int 2019;2019:7643542.

Ciardullo S, Muraca E, Cannistraci R, Perra S, Lattuada G, Perseghin G. Low 25 (OH) vitamin D levels are associated with increased prevalence of NAFLD and significant liver fibrosis. Diabetes Metab Res Rev 2023;93:e3628. doi: 10.1002/dmrr. 3628.

Yuan S, Larsson SC. Inverse association between serum 25 hydroxyvitamin D and nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2023;21:398 405.e394.

Kim Y, Chang Y, Ryu S, Cho IY, Kwon MJ, Sohn W, et al. Resolution of, and risk of incident non alcoholic fatty liver disease with changes in serum 25 hydroxy vitamin D status. J Clin Endocrinol Metab 2022;107:e3437 47.

Thorens B. GLUT2, glucose sensing and glucose homeostasis. Diabetologia 2015;58:221 32.

Munro S, Ceulemans H, Bollen M, Diplexcito J, Cohen PTW. A novel glycogen targeting subunit of protein phosphatase 1 that is regulated by insulin and shows differential tissue distribution in humans and rodents. FEBS J 2005;272:1478 89.

Nakagawa Y, Satoh A, Yabe S, Furusawa M, Tokushige N, Tezuka H, et al. Hepatic CREB3L3 controls whole body energy homeostasis and improves obesity and diabetes. Endocrinology 2014;155:4706 19.

Besse Patin A, Jeromson S, Levesque Damphousse P, Secco B, Laplante M, Estall JL. PGC1A regulates the IRS1: IRS2 ratio during fasting to influence hepatic metabolism downstream of insulin. Proc Natl Acad Sci 2019;116:4285 90.

Paciolla M, Boni R, Fusco F, Pescatore A, Poeta L, Ursini MV, et al. Nuclear factor kappa B inhibitor alpha (NFKBIA) is a developmental marker of NF κB/p65 activation during in vitro oocyte maturation and early embryogenesis. Hum Reprod 2011;26:1191 201.

Yu S, Meng S, Xiang M, Ma H. Phosphoenolpyruvate carboxykinase in cell metabolism: Roles and mechanisms beyond gluconeogenesis. Mol Metab 2021;53:101257. doi: 10.1016/j.molmet.2021.101257.

David Silva A, Esteves JV, Morais M, Freitas HS, Zorn TM, Correa Giannella ML, et al. Dual SGLT1/SGLT2 inhibitor phlorizin ameliorates non alcoholic fatty liver disease and hepatic glucose production in type 2 diabetic mice. Diabetes Metab Syndr Obes 2020;13:739 51.

Stender S, Smagris E, Lauridsen BK, Kofoed KF, Nordestgaard BG, Tybjaerg Hansen A, et al. Relationship between genetic variation at PPP1R3B and levels of liver glycogen and triglyceride. Hepatology 2018;67:2182 95.

Nakagawa Y, Oikawa F, Mizuno S, Ohno H, Yagishita Y, Satoh A, et al. Hyperlipidemia and hepatitis in liver specific CREB3L3 knockout mice generated using a one step CRISPR/Cas9 system. Sci Rep 2016;6:27857. doi: 10.1038/srep27857.